Company intelligence / Profile preview
Phytecs
Los Angeles, California, United Statesphytecs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Phytecs has conducted preclinical work showing encouraging data in assays for epilepsy, schizophrenia, anxiety, and depression[1]. The company's fluorinated cannabidiol (F-CBD) compounds demonstrate greater efficacy and potency than standard CBD, with potential to deliver comparable or greater benefits at lower therapeutic doses[1].
- Therapeutic areas
- PsychiatryImmunologyNeurologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Yissum Research Development Company (Hebrew University of Jerusalem)[1]University of São Paulo (USP)[1]Federal University of Rio Grande Do Sul (UFRGS)[1]
Beyond the preview
Go deeper on Phytecs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phytecs.